Circulating atypical cells detected in blood of lung cancer patients

Circulating atypical cells detected in blood of lung cancer patients Warsaw, October 2021 – New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating...

X-ZELL hMX™ technology now available for research

X-ZELL hMX™ technology now available for research use Singapore, September 2021 – X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the...

X-ZELL launches new Imaging Technology unit

X-ZELL launches new Imaging Technology unit Singapore, August 2021 – Award-winning Singaporean start-up, X-ZELL, has announced the formation of a new, interdisciplinary Imaging Technology division. The announcement comes on the back of a new collaboration agreement...

X-ZELL announces strategic expansion in Europe

X-ZELL announces strategic expansion into Europe Lennestadt, February 2021 – Award-winning Singaporean start-up, X-ZELL, has announced the opening of a new international office in Germany.  Recently voted the second-most innovative health-tech start-up in the world1,...

X-ZELL welcomes new Head of Clinical Development

X-ZELL welcomes new Head of Clinical Development Singapore, November 2020 – X-ZELL, a Singapore start-up specialising in early cancer detection, has announced the appointment of Claire Fives as the company’s new Head of Clinical Development. Fives recently served as...